NCT01817530 2020-07-21
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
AbbVie
Phase 2 Completed
Clinical Trials
18 trialsNCT02811159 2019-06-27
An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT02323646 2019-06-25
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT02301897 2019-06-19
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00958334 2019-06-18
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
Repros Therapeutics Inc.
Phase 2 Completed
NCT03550703 2018-07-06
V3-myoma
Immunitor LLC
Phase 2 Unknown
NCT02131662 2017-12-08
ASTEROID 1
Bayer
Phase 2 Completed
NCT02465814 2016-11-22
ASTEROID 2
Bayer
Phase 2 Completed
NCT01451424 2014-08-29
Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT00958893 2014-08-25
An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00683917 2014-08-21
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Terminated
NCT00882258 2014-07-08
Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 2 Completed
NCT01631903 2014-04-16
Extension of Study ZPV-200
Repros Therapeutics Inc.
Phase 2 Completed
NCT01739621 2014-04-16
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
Repros Therapeutics Inc.
Phase 2 Completed
NCT01452659 2013-01-21
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
Takeda
Phase 2 Completed
NCT00881140 2012-12-19
Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids
BioPro Medical Ltd
Phase 2 Completed
NCT00776074 2010-06-22
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.
Takeda
Phase 2 Completed
NCT00156182 2009-03-04
A Long-Term Safety Study of Asoprisnil in the Treatment of Uterine Fibroids.
Abbott
Phase 2 Completed